Considering that the NF-κB and TGF-β1/Smad signaling cascades were activated during inflammatory and fibrotic phases, respectively, the therapeutic strategy targeting these two pathways may provide a promising effect on PF treatment. This evidence concerns the gene NFKB1 and pemphigus foliaceus.